Affimed (NASDAQ:AFMD) Rating Reiterated by Cantor Fitzgerald

Affimed (NASDAQ:AFMDGet Rating)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report issued on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Affimed’s FY2022 earnings at ($0.63) EPS and FY2023 earnings at ($0.88) EPS.

A number of other brokerages have also issued reports on AFMD. SVB Leerink cut their price target on shares of Affimed from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Thursday, June 23rd. Wells Fargo & Company reiterated an “overweight” rating on shares of Affimed in a research note on Thursday, August 18th. Finally, StockNews.com upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research note on Monday, August 22nd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Affimed Trading Up 0.5 %

NASDAQ:AFMD opened at $2.03 on Wednesday. Affimed has a 52 week low of $1.93 and a 52 week high of $7.35. The firm has a 50 day moving average of $2.83 and a 200 day moving average of $3.30. The company has a quick ratio of 4.89, a current ratio of 4.90 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $250.54 million, a price-to-earnings ratio of -2.94 and a beta of 2.32.

Affimed (NASDAQ:AFMDGet Rating) last issued its quarterly earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. Affimed had a negative net margin of 232.11% and a negative return on equity of 54.94%. The business had revenue of $7.78 million for the quarter, compared to analyst estimates of $8.12 million. As a group, sell-side analysts anticipate that Affimed will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of Affimed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brown Advisory Inc. grew its position in Affimed by 80.0% during the first quarter. Brown Advisory Inc. now owns 90,000 shares of the biopharmaceutical company’s stock valued at $393,000 after buying an additional 40,000 shares during the period. Coastal Bridge Advisors LLC acquired a new stake in Affimed during the fourth quarter valued at $73,000. 683 Capital Management LLC grew its position in Affimed by 5.3% during the fourth quarter. 683 Capital Management LLC now owns 5,900,559 shares of the biopharmaceutical company’s stock valued at $32,571,000 after buying an additional 298,246 shares during the period. Gyon Technologies Capital Management LP acquired a new stake in Affimed during the first quarter valued at $96,000. Finally, Sio Capital Management LLC grew its position in Affimed by 27.6% during the second quarter. Sio Capital Management LLC now owns 821,065 shares of the biopharmaceutical company’s stock valued at $2,274,000 after buying an additional 177,401 shares during the period. Institutional investors and hedge funds own 71.08% of the company’s stock.

About Affimed

(Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.

Featured Stories

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.